{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:19:05Z","timestamp":1793711945419,"version":"4.6.1"},"reference-count":126,"publisher":"Informa UK Limited","issue":"sup2","license":[{"start":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T00:00:00Z","timestamp":1603411200000},"content-version":"unspecified","delay-in-days":45,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Novo Nordisk Inc","id":[{"id":"https:\/\/ror.org\/0435rc536","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Postgraduate Medicine"],"published-print":{"date-parts":[[2020,10,16]]},"DOI":"10.1080\/00325481.2020.1798099","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T06:53:30Z","timestamp":1597906410000},"page":"3-14","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":80,"title":["GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date"],"prefix":"10.1080","volume":"132","author":[{"given":"Stephen A.","family":"Brunton","sequence":"first","affiliation":[{"name":"Touro University California, Vallejo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol H.","family":"Wysham","sequence":"additional","affiliation":[{"name":"MultiCare Rockwood Clinic, Spokane, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0466"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.2337\/ds17-0024"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S009"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0280-5"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S006"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-0331"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.11.015"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13162"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13178"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S130834"},{"key":"cit0011","unstructured":"Ozempic\n                      \u00ae\n                      (semaglutide) prescribing information [updated Jan 2020;\u00a0cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209637s003lbl.pdf"},{"key":"cit0012","unstructured":"Trulicity\n                      \u00ae\n                      (dulaglutide) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125469s033lbl.pdf"},{"key":"cit0013","unstructured":"Victoza\n                      \u00ae\n                      (liraglutide) prescribing information [updated Jun 2019; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022341s031lbl.pdf"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.2337\/diaspect.27.2.100"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.19"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.054"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97233"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00034.2006"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-s227"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12591"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2368"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3070"},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028136"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0566"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21107"},{"key":"cit0027","unstructured":"Byetta\n                      \u00ae\n                      (exenatide) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021773s043lbl.pdf"},{"key":"cit0028","unstructured":"Bydureon\n                      \u00ae\n                      (exenatide extended-release) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/022200s030lbl.pdf"},{"key":"cit0029","unstructured":"Bydureon BCise\n                      \u00ae\n                      (exenatide extended-release) prescribing information [updated Feb 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209210s011lbl.pdf"},{"key":"cit0030","unstructured":"Adlyxin\n                      \u00ae\n                      (lixisenatide) prescribing information [updated Jan 2019; cited 2020 May 25]. Available from: http:\/\/products.sanofi.us\/Adlyxin\/Adlyxin.pdf"},{"key":"cit0031","unstructured":"Xultophy\n                      \u00ae\n                      (liraglutide + insulin degludec) prescribing information [updated Nov 2019; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208583s014s015lbl.pdf"},{"key":"cit0032","unstructured":"Soliqua\n                      \u00ae\n                      (lixisenatide + insulin glargine) prescribing information [updated Nov 2019; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/208673s008s009lbl.pdf"},{"key":"cit0033","unstructured":"Rybelsus\n                      \u00ae\n                      (semaglutide) prescribing information [updated Jan 2020; cited 2020 May 25]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213182s000,213051s001lbl.pdf"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"cit0035","unstructured":"US Food & Drug Administration. FDA approves first oral GLP-1 treatment for type 2 diabetes, 2019 [cited 2020 May 25]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-glp-1-treatment-type-2-diabetes"},{"key":"cit0036","unstructured":"Clinicaltrials.gov. A heart disease study of semaglutide in patients with type 2 diabetes (SOUL). ClinicalTrials.gov Identifier: NCT03914326 [cited 2020 May 25]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03914326"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00826-0"},{"key":"cit0038","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30311-0"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S121991"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0241-z"},{"key":"cit0041","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0476-0"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2019.1618806"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107916"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12575"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-016-0180-0"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2018.11.012"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13137"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14008"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55524-w"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-02175-6"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12804"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12805"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"cit0055","author":"Capehorn MS","journal-title":"Diabetes Metab"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2081"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0424-2"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.06.009"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3082"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2017.1297669"},{"key":"cit0061","unstructured":"US Food & Drug Administration. Guidance document: diabetes mellitus \u2013 evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes, 2008 [cited 2020 May 25]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/diabetes-mellitus-evaluating-cardiovascular-risk-new-antidiabetic-therapies-treat-type-2-diabetes"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509225"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612917"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S188705"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.31.4.148"},{"key":"cit0069","first-page":"45","volume":"21","author":"Milne N","year":"2019","journal-title":"Diabet Prim Care"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13924"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212283"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i581"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0280"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38956-2"},{"key":"cit0075","unstructured":"Byetta\n                      \u00ae\n                      (exenatide) Summary of Product Characteristics [updated Mar 2020; cited 2020 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/byetta-epar-product-information_en.pdf"},{"key":"cit0076","unstructured":"Bydureon\n                      \u00ae\n                      (exenatide extended-release) Summary of Product Characteristics [updated Feb 2020; cited 2020 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bydureon-epar-product-information_en.pdf"},{"key":"cit0077","unstructured":"Lyxumia\n                      \u00ae\n                      (lixisenatide) Summary of Product Characteristics [updated Mar 2020; cited 2020 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lyxumia-epar-product-information_en.pdf"},{"key":"cit0078","unstructured":"Ozempic\n                      \u00ae\n                      (semaglutide) Summary of Product Characteristics [updated Apr 2020; cited 2020 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ozempic-epar-product-information_en.pdf"},{"key":"cit0079","unstructured":"Trulicity\n                      \u00ae\n                      (dulaglutide) Summary of Product Characteristics [updated Nov 2019; cited 2020 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/trulicity-epar-product-information_en.pdf"},{"key":"cit0080","unstructured":"Victoza\n                      \u00ae\n                      (liraglutide) Summary of Product Characteristics [updated Nov 2019; cited 2020 May 25]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/victoza-epar-product-information_en.pdf"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2020.1798162"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13538"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13484"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13172"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.12.001"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2"},{"key":"cit0088","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00070"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"cit0090","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30066-X"},{"key":"cit0091","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-S011"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.657"},{"key":"cit0093","doi-asserted-by":"crossref","unstructured":"Tougaard RS, Jorsal A, Tarnow L, et al. Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events [published online ahead of print, 2020 Apr 15]. Scand Cardiovasc J. 2020;1\u20136.","DOI":"10.1080\/14017431.2020.1751873"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-015-0199-z"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1421146"},{"key":"cit0097","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0470-y"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S151736"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12902"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-014-0166-0"},{"key":"cit0101","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S161151"},{"key":"cit0102","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0617-3"},{"key":"cit0103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"cit0104","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-1144"},{"key":"cit0105","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0260-x"},{"key":"cit0106","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S187907"},{"key":"cit0107","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S106821"},{"key":"cit0108","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0819-5"},{"key":"cit0109","doi-asserted-by":"publisher","DOI":"10.2337\/cd18-0034"},{"key":"cit0110","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar7047"},{"key":"cit0111","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2013.02.030"},{"key":"cit0112","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0728-4"},{"key":"cit0113","unstructured":"Novo Nordisk. Rybelsus\n                      \u00ae\n                      approved in Japan for the treatment of type 2 diabetes, 2020 [cited 2020 Jul 7]. Available from: https:\/\/www.novonordisk.com\/media\/news-details.2325697.html"},{"key":"cit0114","unstructured":"Rybelsus\n                      \u00ae\n                      product monograph including patient medication information; date of initial approval: March 30, 2020 [cited 2020 Jun 24]. Available from: https:\/\/www.novonordisk.ca\/content\/dam\/Canada\/AFFILIATE\/www-novonordisk-ca\/OurProducts\/PDF\/Rybelsus-PM-EN-monograph.pdf"},{"key":"cit0115","unstructured":"Rybelsus\n                      \u00ae\n                      Summary of Product Characteristics [updated Jun 2020; cited 2020 Jun 24]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rybelsus-epar-product-information_en.pdf"},{"key":"cit0116","unstructured":"Rybelsus\n                      \u00ae\n                      Swiss public assessment report; decision date: 24 March 2020 [cited 2020 Jun 24]. Available from: https:\/\/www.swissmedic.ch\/dam\/swissmedic\/de\/dokumente\/zulassung\/swisspar\/67446-rybelsus-01-swisspar-20200430.pdf.download.pdf\/SwissPAR_Rybelsus_final.pdf"},{"key":"cit0117","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0749"},{"key":"cit0118","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0883"},{"key":"cit0119","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2942"},{"key":"cit0120","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31271-1"},{"key":"cit0121","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30192-5"},{"key":"cit0122","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118"},{"key":"cit0123","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30194-9"},{"key":"cit0124","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0898"},{"key":"cit0125","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30074-7"},{"key":"cit0126","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(20)30075-9"}],"container-title":["Postgraduate Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00325481.2020.1798099","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T13:16:20Z","timestamp":1620566180000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00325481.2020.1798099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":126,"journal-issue":{"issue":"sup2","published-print":{"date-parts":[[2020,10,16]]}},"alternative-id":["10.1080\/00325481.2020.1798099"],"URL":"https:\/\/doi.org\/10.1080\/00325481.2020.1798099","relation":{},"ISSN":["0032-5481","1941-9260"],"issn-type":[{"value":"0032-5481","type":"print"},{"value":"1941-9260","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ipgm20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}